日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Integration of Ki67 and Pan-Immune-Inflammation Value (PIV) into a predictive nomogram for pathologic complete response in triple-negative breast cancer : (Ki67 and inflammation in triple-negative breast cancer)

将 Ki67 和泛免疫炎症值 (PIV) 整合到三阴性乳腺癌病理完全缓解预测列线图中:(Ki67 和三阴性乳腺癌的炎症)

Guclu-Kantar, Taliha; Tanriverdi, Ozgur; Bayrakci, Ismail; Demir, Bilgin; Colak, Gokhan; Kitaplı, Sait; Alkan, Ali; Gokoz-Doğu, Gamze; Topaloglu, Sernaz; Barutca, Sabri

Integration of the GRIm Score with Pathologic Immune and Stromal Markers to Develop a Combined Prognostic Model in Gastric Cancer: A Retrospective Single-Center Study

将GRIm评分与病理免疫和间质标志物整合,构建胃癌联合预后模型:一项回顾性单中心研究

Öztürk, Gökhan; Taştekin, Ebru; Topuz, Canberk; Akkuş, Aysun Fatma; Aydın, Tayyip İlker; Topaloğlu, Sernaz; Erdoğan, Bülent; Hacıoğlu, Muhammet Bekir; Küçükarda, Ahmet

Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis

采用倾向评分匹配法比较单侧乳腺癌和双侧乳腺癌的生存率:一项回顾性单中心分析

Ozler, Talar; Cosar, Rusen; Sut, Necdet; Nurlu, Dilek; Parlar, Şule; Ateş, Sinan; Dertli, Mert Hacı; Kavuzlu, Yusuf; Kavukcu, Sekip; Chousein, Mert; Yıldız, Gokay; Tunçbilek, Nermin; Hacıoglu, Muhammet Bekir; Tastekin, Ebru; Topaloğlu, Sernaz

Prognostic value of the HALP score in metastatic castration-resistant prostate cancer: an analysis combined with time to castration resistance

HALP评分在转移性去势抵抗性前列腺癌中的预后价值:结合去势抵抗时间的分析

Gökmen, İvo; Demir, Nazan; Peker, Pınar; Özcan, Erkan; Akgül, Fahri; Bayrakçı, İsmail; Divriklioğlu, Didem; Erdoğan, Bülent; Topaloğlu, Sernaz; Hacıoğlu, Muhammet Bekir

Retrospective evaluation of the contribution of radiotherapy to survival in breast cancer treatment with propensity score based on stage and subgroup

基于分期和亚组的倾向评分,回顾性评估放射治疗对乳腺癌生存率的贡献

Cosar, Rusen; Sut, Necdet; Parlar, Sule; Ozguven, Yıldıray; Nurlu, Dilek; Tastekin, Ebru; Batu, Sena; Şenödeyici, Eylül; Ozler, Talar; Dedeli, Melisa; Yıldız, Gökay; Kavukcu, Sekip; Chousein, Mert; Alas, Zeynep; Topaloglu, Sernaz

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer

结直肠癌中KRAS/NRAS和BRAF突变的分子模式和临床意义

Gökmen, İvo; Taştekin, Ebru; Demir, Nazan; Özcan, Erkan; Akgül, Fahri; Hacıoğlu, Muhammed Bekir; Erdoğan, Bülent; Topaloğlu, Sernaz; Çiçin, İrfan

PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score

PNI 作为潜在的附加生物标志物,可改善 IMDC 中期预后评分

Bayoğlu, İbrahim Vedat; Hüseynov, Javid; Topal, Alper; Sever, Nadiye; Majidova, Nargiz; Çelebi, Abdussamet; Yaşar, Alper; Arıkan, Rukiye; Işık, Selver; Hacıoğlu, Muhammet Bekir; Ercelep, Özlem; Sarı, Murat; Erdoğan, Bülent; Hacıbekiroğlu, İlhan; Topaloğlu, Sernaz; Köstek, Osman; Çiçin, İrfan

BRCA 1/BRCA 2 Pathogenic/Likely Pathogenic Variant Patients with Breast, Ovarian, and Other Cancers

携带 BRCA 1/BRCA 2 致病性/可能致病性变异的乳腺癌、卵巢癌及其他癌症患者

Osman, K; Ahmet, K; Hilmi, T; İlker, N O; Ercan, Ö; Devrim, Ç; Murat, S; Emre, Ç; İlhan, H; Mustafa, G; Yüksel, Ü; Bahiddin, Y; Cihan, E; Mehmet Ali, N Ş; Emrah, E; Umut, D; Zeynep, O; Mehmet Ali, K; Ali, G; İvo, G; Erkan, Ö; Muhammet, B H; Bülent, E; Selma, D; Sernaz, U; Mahmut, G; Hakan, G; İrfan, Ç

Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series

乳腺癌亚型与预后:亚组分类问题的解答,以及我们单中心系列研究中最差亚组的识别

Cosar, Rusen; Sut, Necdet; Ozen, Alaattin; Tastekin, Ebru; Topaloglu, Sernaz; Cicin, Irfan; Nurlu, Dilek; Ozler, Talar; Demir, Seda; Yıldız, Gokay; Şenödeyici, Eylül; Uzal, Mustafa Cem

Unknown primary adenocarcinomas: a single-center experience

原发灶不明的腺癌:单中心经验

Uzunoglu, Sernaz; Erdogan, Bulent; Kodaz, Hilmi; Cinkaya, Ahmet; Turkmen, Esma; Hacibekiroglu, Ilhan; Sari, Ali; Ozen, Alaattin; Usta, Ufuk; Cicin, Irfan